Effect of Apatinib Mesylate Combined with FOLFOX Regimen on Patients with Advanced Colorectal Cancer and Its Influence on Serum Tumor Markers
Objective:To explore the effect of Apatinib Mesylate combined with FOLFOX regimen on patients with advanced colorectal cancer(CRC)and its influence on serum tumor markers,growth differentiation factor-15(GDF-15)and serum insulin-like growth factor binding protein 7(IGFBP7)levels.Method:A total of 72 patients with advanced CRC admitted to the Fourth Affiliated Hospital of Nanchang University and Nanchang County People's Hospital from January 2018 to January 2021 were selected as the study objects,and divided into control group(n=36)and observation group(n=36)according to different treatment regimen.The control group was given FOLFOX regimen,and the observation group was given Apatinib Mesylate + FOLFOX regimen.Objective response rate(ORR),serum tumor markers levels,GDF-15,IGFBP7,survival situation and adverse reactions of the two groups were observed.Result:The ORR of observation group was higher than that of control group,the difference was statistically significant(P<0.05).After treatment,the levels of GDF-15,IGFBP7,carcinoembryonic antigen(CEA)and carbohydrate antigen 50(CA50)in observation group were significantly lower than those in control group,the differences were statistically significant(P<0.05).There were no significant differences in the incidence of adverse reactions between the two groups(P>0.05).After 2 years of follow-up,Kaplan-Meier curve showed that the cumulative survival rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).Conclusion:Apatinib Mesylate combined with FOLFOX regimen can improve the ORR and cumulative survival rate of patients with advanced CRC,and reduce the levels of GDF-15,IGFBP7 and serum tumor markers.
国家科技期刊平台
NSTL
万方数据
